Abstract: The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.

Abstract: The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.

Abstract: The invention concerns an assembly consisting of an aqueous oxaliplatin solution and a glass flask containing same, characterised in that the surface/volume ratio of the flask, expressed in mm2/mm3, is less than 0.26.

Abstract: The invention concerns a pharmaceutically stable oxaliplatinum preparation for parenteral administration, the oxaliplatinum being in a precipitate-free, colorless and clear solution after being preserved for a pharmaceutical acceptable duration. In said preparation, the oxaliplatinum is contained in a solution in a solvent at a concentration of at least 7 mg/ml and the solvent comprises a sufficient amount of at least a hydroxylated derivative selected among 1,2-propane-diol, glycerol, maltitol, saccharose and inositol. The invention also concerns a method for preparing said solution.

Abstract: The present invention relates to a stable pharmaceutical preparation of oxaliplatin for parenteral administration, in which the oxaliplatin is in solution in a solvent at a concentration of at least 7 mg/ml, which has been subjected to an operation of wet heat treatment with steam in the saturation state and under pressure at a high temperature not exceeding 110° C. It also relates to the method for the production thereof.

Abstract: The invention concerns an assembly consisting of an aqueous oxiplatinum solution and a glass flask containing same, characterised in that the surface/volume ratio of the flask, expressed in mm2/mm3, is less than 0.26.

Abstract: The present invention relates to an oxaliplatin active substance for a pharmaceutical composition, wherein its weight content in oxalic acid is not more than 0.08%, and to a process of preparing the active substance.

Abstract: The present invention relates to a stable pharmaceutical preparation of oxaliplatin for parenteral administration, in which the oxaliplatin is in solution in a solvent at a concentration of at least 7 mg/ml, which has been subjected to an operation of wet heat treatment with steam in the saturation state and under pressure at a high temperature not exceeding 110° C. It also relates to the method for the production thereof.

Abstract: The invention relates to pharmaceutical compositions containing cinchonine dihydrochloride as active ingredient with a purity of at least 95%. The invention also relates to a process for preparing cinchonine dihydrochloride from cinchonine and the use of pharmaceutical compositions containing cinchonine dihydrochloride for treating multiple drug resistance.

Abstract: The invention relates to pharmaceutical compositions containing cinchonine dihydrochloride as active ingredient with a purity of at least 95%. The invention also relates to a process for preparing cinchonine dihydrochloride from cinchonine and the use of pharmaceutical compositions containing cinchonine dihydrochloride for treating multiple drug resistance.

Abstract: A pharmaceutically stable oxaliplatinum preparation for parenteral administration comprises an aqueous solution of oxaliplatinum, in a concentration of 1 to 5 mg/ml, and with a pH in the range of 4.5 to 6. The aqueous oxaliplatinum solution is advantageously provided as a ready-to-use preparation in a sealed container.